Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK approves gene therapy trial for glioma:

This article was originally published in Clinica

Executive Summary

The UK's Gene Therapy Advisory Committee (GTAC) has approved the launch of a large-scale clinical trial of a new treatment for glioma. Glioma is one of the most aggressive types of brain tumours and for which there is currently no cure. The technique being studied by Glasgow University's neurovirology department, led by Professor Moira Brown, involves injecting a Herpes simplex virus - modified to target cancerous cells but leave normal cells undamaged - into the tumour. GTAC has approved 90 gene therapy clinical trials involving over 700 patients, since 1993. 72% of these are for cancer.

You may also be interested in...



FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

Stada Grabs GSK Brands In EU

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.

Topics

UsernamePublicRestriction

Register

MT059321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel